AGTI Stock Cash Flow Statements

Agiliti Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Agiliti Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities:
consolidated net income	-6,516,000	-5,619,000	-12,622,000	-3,928,000	3,050,000	3,471,000	1,989,000	5,063,000	19,920,000	9,728,000	-5,171,000	9,583,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	20,980,000	20,819,000	20,272,000	19,538,000	19,620,000	18,829,000	19,090,000	23,914,000	22,498,000	25,365,000	26,667,000	26,217,000
amortization	20,675,000	23,206,000	23,619,000	23,385,000	23,473,000	24,198,000	24,135,000	23,761,000	23,358,000	22,527,000	22,556,000	18,399,000
remeasurement of tax receivable agreement	267,000											4,148,000
benefit from credit losses	-1,371,000	-81,000	2,045,000	-63,000	404,000	3,102,000	522,000
benefit from inventory obsolescence	945,000	8,000	588,000	340,000	789,000	175,000	291,000	243,000	325,000	313,000	694,000	1,532,000
non-cash share-based compensation expense	4,238,000	4,325,000	5,387,000	3,585,000	6,889,000	3,709,000	4,860,000	5,569,000	4,637,000	4,361,000	3,354,000	2,412,000
gain on sales and disposals of equipment	-279,000	98,000	-252,000	-426,000	-751,000	-308,000	-537,000	337,000	-593,000	-3,099,000	-193,000	-647,000
deferred income taxes	-6,767,000	-2,011,000	-3,310,000	-7,771,000	-4,229,000	4,657,000	-798,000	-6,965,000	4,398,000	7,346,000	762,000	3,932,000
changes in operating assets and liabilities:
accounts receivable	-28,877,000	-2,450,000	5,233,000	3,384,000	-15,497,000	-7,396,000	12,253,000	-2,621,000	-6,212,000	-36,352,000	3,149,000	2,898,000
inventories	-12,467,000	5,394,000	-622,000	-5,920,000	-4,399,000	-5,649,000	-2,141,000	-3,426,000	-972,000	2,655,000	-5,055,000	3,641,000
other operating assets	5,431,000	-7,160,000	1,283,000	415,000	3,930,000	-2,578,000	-6,987,000	-1,711,000	1,132,000	-4,980,000	-638,000	226,000
accounts payable	7,386,000	-10,457,000	928,000	2,671,000	7,935,000	2,630,000	4,421,000	3,351,000	5,351,000	-651,000	3,991,000	1,361,000
accrued and other operating liabilities	10,117,000	-5,459,000	23,111,000	-12,132,000	13,682,000
net cash from operating activities	13,762,000	21,655,000	65,742,000	27,523,000	54,896,000	37,875,000	60,763,000	34,014,000	67,124,000	30,905,000	44,599,000	62,909,000
cash flows from investing activities:
medical equipment purchases	-11,870,000	-16,158,000	-10,448,000	-13,384,000	-12,128,000	-18,370,000	-14,671,000	-12,818,000	-10,005,000	-7,643,000	-11,854,000	-4,415,000
property and office equipment purchases	-6,674,000	-9,151,000	-9,375,000	-8,970,000	-6,734,000	-11,226,000	-7,598,000	-7,561,000	-5,215,000	-4,927,000	-6,697,000	-3,915,000
proceeds from disposition of property and equipment	806,000	779,000	1,001,000	1,082,000	1,033,000	268,000	932,000	1,119,000	644,000	6,174,000	1,010,000	1,003,000
intangible asset purchases	-27,000
net cash from investing activities	-17,765,000	-25,969,000	-18,822,000	-21,272,000	-17,829,000	-88,562,000	-21,337,000	-22,385,000	-14,576,000	-6,396,000	-17,541,000	-457,525,000
cash flows from financing activities:
proceeds under debt arrangements	70,000,000	36,000,000	58,000,000	1,121,937,000	87,000,000	40,000,000	0
payments under debt arrangements	-65,688,000	-38,688,000	-78,000,000	-1,122,200,000	-82,849,000	-13,850,000	-22,349,000
payments of principal under finance lease liability	-2,351,000	-2,460,000	-2,355,000	-2,390,000	-2,297,000	-2,136,000	-2,192,000	-2,261,000	-2,223,000	-2,451,000	-2,219,000	-2,051,000
payments of deferred financing costs	-871,000	-1,000	-89,000
payments under tax receivable agreement	-10,938,000	0	0	0	-24,822,000							-748,000
distributions to noncontrolling interests	-55,000	-66,000	-64,000	-50,000	-57,000	-54,000	-53,000	-15,000	-32,000	-55,000	-33,000	-50,000
proceeds from exercise of stock options	1,150,000	387,000	568,000	1,633,000	469,000	152,000	978,000
dividend and equity distribution payment		0	0	0	-321,000	0	-2,000					-924,000
shares forfeited for taxes	-1,908,000	-9,000	-46,000	-932,000	-5,314,000	-59,000	-121,000
net cash from financing activities	-10,661,000	-6,035,000	-25,747,000	-11,491,000	-28,191,000	24,053,000	-23,739,000	-47,208,000	-74,770,000	-4,466,000	63,284,000	201,439,000
net change in cash and cash equivalents	-14,664,000	-10,349,000	21,173,000	-5,240,000	8,876,000	-26,634,000	15,687,000	-35,579,000	-22,222,000	20,043,000	90,342,000	-193,177,000
cash and cash equivalents at the beginning of period	20,037,000	0	0	0	5,577,000	0	0	0	74,325,000	0	0	206,505,000
cash and cash equivalents at the end of period	5,373,000	-10,349,000	21,173,000	-5,240,000	14,453,000	-26,634,000	15,687,000	-35,579,000	52,103,000	20,043,000	90,342,000	13,328,000
supplemental cash flow information:
interest paid	22,050,000	21,914,000	8,725,000	15,723,000	14,622,000	12,559,000	11,050,000	9,641,000	9,523,000	9,974,000	11,271,000	19,746,000
income taxes paid	88,000	732,000	1,594,000	9,451,000	39,000	1,671,000	1,547,000			1,106,000
loss on extinguishment / modification of debt		0	82,000
acquisitions, net of cash acquired						-59,214,000	0					-450,198,000
proceeds from issuance of common stock
purchases of treasury stock		0
stock issuance costs
acquisition holdback and contingent consideration
the accompanying notes are an integral part of these consolidated financial statements.
payments of contingent consideration						0	0
loss on extinguishment of debt						0	0
other operating liabilities							3,665,000	-15,225,000	-6,691,000	2,947,000	-13,985,000	-10,811,000
benefit from credit (gains) losses									-27,000
proceeds under revolver
proceeds under term loan
payments under term loan

income taxes (refund) paid									604,000			-715,000
remeasurement of tax receivable agreement and contingent consideration
benefit from doubtful accounts										548,000	555,000	18,000
payments under revolver
change in book overdrafts
proceeds under new revolver												10,000,000
payments under new revolver
proceeds under new term loan												198,052,000
payments under new term loan												-2,840,000
collection of note receivable from officer
acquisition of agiliti health, inc. by thl shareholders
payments under senior secured credit facility
repayments of 2012 notes
shares repurchased
redemption of warrants
contribution from new members to limited liability company
intangible asset impairment charge
gain on settlement
amortization of intangibles, contract costs, deferred financing costs and bond premium
interest on note receivable
issuance of note receivable from officer
acquisitions and refund of escrow
proceeds under senior secured credit facility
payments of principal under capital lease obligations
payment of deferred financing costs
holdback and earn-out payments related to acquisitions
dividend and equity distribution payments
proceeds from exercise of parent company stock options
contribution from parent
non-cash activities:
medical equipment purchases included in accounts payable
capital lease additions

We provide you with 20 years of cash flow statements for Agiliti stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Agiliti stock. Explore the full financial landscape of Agiliti stock with our expertly curated income statements.

The information provided in this report about Agiliti stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.